Developing mRNA-based vaccines for HIV
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of mRNA, Lipid Nanoparticle Based HIV Immunogens
['FUNDING_OTHER'] · DUKE UNIVERSITY · NIH-10927030
This study is working on new mRNA vaccines to help prevent and treat HIV, using special tiny particles to deliver the vaccine effectively, and it aims to eventually test these vaccines in people to improve options for those living with HIV.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-10927030 on ClinicalTrials.gov |
What this research studies
This research focuses on the development and manufacturing of mRNA vaccines aimed at combating HIV. It involves creating and testing immunogens, which are substances that provoke an immune response, using lipid nanoparticles to enhance delivery. The project encompasses all stages from small-scale production to preclinical testing, ultimately leading to clinical trials for potential vaccines. Patients may benefit from advancements in HIV prevention and treatment through innovative vaccine technologies.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit include individuals at high risk for HIV infection or those living with HIV seeking new treatment options.
Not a fit: Patients who are not at risk for HIV or those who have already achieved viral suppression may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective vaccines that significantly reduce the risk of HIV infection.
How similar studies have performed: Previous research has shown promise in using mRNA technology for vaccine development, particularly in other viral infections, indicating a potential for success in this area as well.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BERES, WENDELL — DUKE UNIVERSITY
- Study coordinator: BERES, WENDELL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus